Inovio Net Income from 2010 to 2026
| INO Stock | USD 1.70 0.07 4.29% |
Net Loss | First Reported 1998-12-31 | Previous Quarter -23.5 M | Current Value -45.5 M | Quarterly Volatility 23.8 M |
Check Inovio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inovio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 194.3 K or Total Revenue of 237.9 K, as well as many indicators such as Price To Sales Ratio of 195, Dividend Yield of 0.0053 or PTB Ratio of 0.62. Inovio financial statements analysis is a perfect complement when working with Inovio Pharmaceuticals Valuation or Volatility modules.
Inovio | Net Income | Build AI portfolio with Inovio Stock |
Evaluating Inovio Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Inovio Pharmaceuticals's fundamental strength.
Latest Inovio Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Inovio Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Inovio Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Inovio Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Inovio Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inovio Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (107.25 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Inovio Net Income Regression Statistics
| Arithmetic Mean | (102,428,006) | |
| Coefficient Of Variation | (82.13) | |
| Mean Deviation | 58,476,540 | |
| Median | (96,528,713) | |
| Standard Deviation | 84,128,477 | |
| Sample Variance | 7077.6T | |
| Range | 297.1M | |
| R-Value | (0.62) | |
| Mean Square Error | 4649.7T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | (10,325,051) | |
| Total Sum of Squares | 113241.6T |
Inovio Net Income History
Other Fundumenentals of Inovio Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Inovio Pharmaceuticals Net Income component correlations
About Inovio Pharmaceuticals Financial Statements
Inovio Pharmaceuticals investors utilize fundamental indicators, such as Net Income, to predict how Inovio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -96.5 M | -101.4 M | |
| Net Loss | -96.5 M | -101.4 M | |
| Net Loss | -96.5 M | -101.4 M | |
| Net Loss | (4.54) | (4.77) | |
| Net Income Per E B T | 0.89 | 0.79 |
Pair Trading with Inovio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inovio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inovio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Inovio Stock
Moving against Inovio Stock
| 0.53 | GILD | Gilead Sciences Earnings Call This Week | PairCorr |
| 0.51 | VYNE | Vyne Therapeutics | PairCorr |
| 0.49 | VRTX | Vertex Pharmaceuticals Earnings Call Tomorrow | PairCorr |
| 0.49 | FBIO | Fortress Biotech | PairCorr |
| 0.4 | KOD | Kodiak Sciences | PairCorr |
The ability to find closely correlated positions to Inovio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inovio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inovio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inovio Pharmaceuticals to buy it.
The correlation of Inovio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inovio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inovio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inovio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Inovio Pharmaceuticals Correlation against competitors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Biotechnology sector continue expanding? Could Inovio diversify its offerings? Factors like these will boost the valuation of Inovio Pharmaceuticals. Market participants price Inovio higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Inovio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.84) | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
Understanding Inovio Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Inovio's accounting equity. The concept of intrinsic value—what Inovio Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Inovio Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Inovio Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.